Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Novartis and Bristol Myers Squibb halt clinical trials following serious side effects

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

regulatory

◆ Sectors

BiotechDrug Discovery

◆ Source

Read at medwatch.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

Novartis and Bristol Myers Squibb have paused clinical trials due to serious side effects observed, raising safety concerns and potential regulatory scrutiny in the pharmaceutical sector.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 2 sources have reported it between 31 Aug 2026 and 2 Sep 2026.

◆ ◆ The Wire takeaway

You must tighten safety protocols and prepare for tougher drug approval processes following trial halts by Novartis and Bristol Myers Squibb. This pause signals regulators are taking increased action on adverse trial events.

◆ Coverage

2 sources · first reported 31 Aug 2026 · latest 2 Sep 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryclinical-trialspharma-safetyregulatory-riskdrug-development